Biologics Contract Manufacturing Market Set to Witness an Uptick during 2022 to 2030Posted by Mrudula Anil Karmarkar on August 2nd, 2023 San Francisco, 02 August 2023: The ReportBiologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (MABs, Recombinant Protein), By Indication (Oncology, CVDs), By Region (Europe, APAC), And Segment Forecasts, 2022 - 2030 The global biologics contract manufacturing market size is expected to reach USD 34.7 billion by 2030, registering a CAGR of 10.5% over the forecast period, according to a new report by Grand View Research, Inc. The global market was growing efficiently during the COVID-19 pandemic. This is due to a rise in R&D activities for the development of COVID-19 vaccines. In addition, there has been an expansion in manufacturing facilities to control the spread of the disease. For instance, in November 2021, Lonza announced that it has decided to expand its microbial development laboratories in Switzerland to support the company’s upcoming projects. It is believed that post-pandemic there will be numerous fundamental changes. There will be an increase in the production and manufacturing efforts for the development of vaccines and therapeutics against the coronavirus and a rise in digital capabilities across all their operating units. These initiatives will help them in joint planning with pharma clients in building more strategic partnerships. For instance, in January 2022, Lonza launched a technology that will be used for the discovery and design of antibodies that are biospecific and this technology will be called bYlok™. The outsourcing of drugs or biologics manufacturing is rapidly increasing around the world. Pharmaceutical and biotechnology companies concentrate on their core projects while reducing the operational costs associated with manufacturing drugs or biologics. Contract Manufacturing Organizations (CMOs) are specialized and experienced in conducting the entire process of manufacturing. In-house manufacturing of biologics is difficult as it is a complex process and involves many resources. CMOs link the demand and supply gap by focusing on improving the drug discovery process resulting in faster availability of biologics for patients. Hence, due to these factors, outsourcing activities are rapidly increasing. There was unparalleled growth in 2020 due to the COVID-19 pandemic. The main drivers for this growth were the rise in investments by the government and prominent players in the biopharmaceutical market to increase productivity and efficiency. Biotechnology outsourcing of biologics has become a new trend. Biotech contract manufacturing is witnessing an increase in inquiries as well as orders, mostly related to coronavirus vaccines and therapeutics. Currently, Lonza has received over 40 inquiries about projects related to COVID-19. The COVID-19 pandemic has resulted in the disruptions in the supply chain. Request sample report of Biologics Contract Manufacturing Market@https://www.grandviewresearch.com/industry-analysis/biologics-contract-manufacturing-market-report/request/rs1 Biologics Contract Manufacturing Market Report Highlights
However, supply chains have proven to be robust and supplies, manufacturing as well as services associated with biologics, have remained largely unaffected around the globe. Many organizations are attempting to speed up their productivity to meet the growing demand. Such companies are, therefore, appointing CDMOs to speed up their production processes. The worldwide effort to develop a vaccine against COVID-19 has created the greatest opportunity for many large CDMOs. Continuous advancements in biotechnology and biomedical science techniques have dramatically enhanced the process of biologics development for the management of several chronic conditions. Biologics Contract Manufacturing Market Report Scope
List of Key Players in Biologics Contract Manufacturing Market
Have a Query? Ask Our Expert:https://www.grandviewresearch.com/inquiry/452624/ibb Like it? Share it!More by this author |